Coverage for Parkinson's and Alzheimer's patients.
Summary
SB 185 would add a new section to Indiana insurance law prohibiting health plans from requiring prior authorization for health care services used to diagnose or treat Alzheimer’s disease, dementia, related cognitive disorders, or Parkinson’s disease. In practical terms, the bill would make it easier for patients with these conditions to access covered diagnostic testing, specialist visits, and treatment services without first getting insurer approval for each service.
The bill is narrowly focused on a specific set of neurodegenerative and cognitive conditions and applies to participating providers within a health plan network. It does not appear to change eligibility for coverage or mandate that a plan cover services it otherwise would not cover; rather, it removes the prior-authorization step for services tied to these diagnoses and treatments.
Impact
The bill would amend the Indiana Code by adding IC 27-1-37.5-18, creating a new insurance requirement effective July 1, 2025. It would restrict health plans from imposing prior authorization on services used to diagnose or treat Alzheimer’s disease, dementia, related cognitive disorders, and Parkinson’s disease, thereby affecting insurers, managed care plans, participating providers, and patients receiving care for these conditions.
Sentiment
Based on the bill’s caption and the absence of recorded committee debate or votes in the provided materials, the bill appears to be framed as a patient-access measure with a generally supportive policy rationale. The proposal is consistent with efforts to reduce administrative barriers for individuals facing serious neurodegenerative illnesses, and there is no evidence in the supplied record of organized opposition or amendment activity.
Contention
The main policy issue likely to arise is whether eliminating prior authorization could increase utilization and costs for health plans, versus the argument that prior authorization can delay needed care and burden patients and providers. Supporters would likely emphasize faster access to diagnosis and treatment for vulnerable patients, while insurers or managed care interests could be concerned about reduced utilization management and potential premium impacts. No specific contested points are documented in the provided committee or voting history.